Clinical trials: Allogenic Disease
Acute Lymphoblastic Leukemia
Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation
Multiple conditioning regimens have been used for the HSCT, some of which include radiotherapy. Total body irradiation (TBI) has demonstrated to be superior to chemotherapy alone in the phase III FORUM trial.
- Trial name
- NCT06209190
- Testing
- total marrow and total lymphoid irradiation
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
B-cell Acute Lymphoblastic Leukemia
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric…
- Trial name
- NCT06080191
- Testing
- CD19-CAR_Lenti_ALLO
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Chronic Graft-Versus-Host Disease, Allogeneic Stem Cell Transplant
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic…
- Trial name
- NCT05690971
- Testing
- App, Usual Care
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia
The Efficacy of Allo-HSCT in ND HR-CBF-AML
For newly diagnosed high-relapse-risk core-binding-factor acute myeloid leukemia participants, the investigators aim to perform allogeneic hematopoietic stem cell transplantation after participants finished one cycle of induction…
- Trial name
- NCT06458244
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Chemotherapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Ruijin Hospital
Renal Dysfunction, Acute Renal Failure
Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol
The purpose of the study is to combine Urodilatin (ANP analogue), which will increase glomerular filtration rate (GFR), and mannitol, which will increase the rate of urinary flow and solute excretion.
- Conditions
- Renal Dysfunction, Acute Renal Failure, Mortality
- Trial name
- NCT00390624
- Testing
- URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE), MANNITOL
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rocky Mountain Cancer Centers
Leukemia, Chronic Myeloid Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell…
- Conditions
- Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large Cell Lymphoma
- Trial name
- AlloTreo (NCT00598624)
- Testing
- Treosulfan IV
- Where
- 12 sites in Italy
- Volunteers
- 175 people
- Sponsor
- IRCCS San Raffaele
SLE - Systemic Lupus Erythematosus
Allogeneic UCB-derived CAR-T for SLE
The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults.
- Trial name
- NCT07274059
- Testing
- allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Chengdu Ucello Biotechnology Co., Ltd.
Hematologic Neoplasms
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Allogeneic (Allo) hematopoietic stem cell transplantation (HSCT) is a recognized curative procedure for hematological malignancies.
- Trial name
- HAPLOMUD (NCT02623309)
- Testing
- Allogeneic (Allo) hematopoietic stem cell transplantation
- Where
- 14 sites in France
- Volunteers
- 108 people
- Sponsor
- Institut Paoli-Calmettes
Relapsed Hematologic Malignancy, Multiple Myeloma
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Multiple Myeloma (MM) is a morbid disease which can only be cured with an allogeneic hematopoietic stem cell transplant (HSCT). Approximately 50% of allotransplanted patients will relapse, with a median survival of 5 years.
- Trial name
- NCT03413800
- Testing
- Lenalidomide-Dexamethasone-DLI
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
AML
Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML
The goal of this study is to evaluate the efficacy and safety of a conditioning regimen of Mitoxantrone Hydrochloride Liposome in combination with Bu/Cy (M+Bu/Cy) on acute myeloid leukaemia (AML) patients with…
- Trial name
- NCT06758726
- Testing
- Mitoxantrone Hydrochloride Liposome combined with BU/Cy
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Myelodysplastic Syndromes, Acute Leukemia
Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia
RATIONALE: Giving chemotherapy and total marrow and lymphoid irradiation before allogeneic hematopoietic cell transplant helps stop the growth of leukemia cells.
- Trial name
- NCT03408210
- Testing
- total body irradiation, total marrow and lymphoid irradiation
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Graft Versus Host Disease, GVHD
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell…
- Trial name
- NCT00282282
- Testing
- tacrolimus, sirolimus, fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis
Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.
The goal of this study is to collect clinical data and samples and to evaluate the feasibility of allogeneic hematopoietic cell transplantation (HCT) in children and young adults with refractory Systemic Juvenile Idiopathic…
- Conditions
- Refractory Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis Associated Lung Disease
- Trial name
- NCT07845942
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Graft Versus Host Disease, Leukemia
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00014469
- Testing
- busulfan, melphalan, methotrexate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neutropenic Enterocolitis, Myeloablative Chemotherapy Induced Bone Marrow Aplasia
Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis
Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent…
- Trial name
- NCT02145923
- Testing
- Peripheral blood stem cell mobilisation and collection, High-dose chemotherapy, Bone marrow derived allogeneic MMSCs infusion
- Where
- Russia
- Volunteers
- 16 people
- Sponsor
- Burnasyan Federal Medical Biophysical Center
Allograft, Allogeneic Cell Transplantaion
A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
This study is a prospective comparison between 2 popular regimens based on reduced intensity or non-myeloablative approaches to define the optimal myeloablative and/or immu-nonsuppressive association for reduced intensity…
- Conditions
- Allograft, Allogeneic Cell Transplantaion, Hematological Malignancy, Solid Tumor
- Trial name
- ITAC02-01 (NCT00894049)
- Testing
- reduced intensity conditionings
- Where
- 5 sites in France
- Volunteers
- 148 people
- Sponsor
- Institut Paoli-Calmettes
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Cerebral Palsy
Human Umbilical Cord Blood Infusion in Patients with Cerebral Palsy
A phase I, randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral palsy
- Trial name
- NCT06377982
- Testing
- hUCB
- Volunteers
- 12 people
- Sponsor
- StemCyte Taiwan Co., Ltd.
Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse is the most common problem affecting long-term survivors of allo-HSCT.
- Trial name
- NCT03662087
- Testing
- HMA+DLI, DLI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation
This open label phase-II trial evaluates hematological response of an additional treatment with 5-Azacitidine to common DLI in patients with MDS or AML relapsing after allogeneic stem cell transplantation.
- Trial name
- NCT00795548
- Testing
- 5-Azacitidine
- Where
- 6 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.